HBV核苷类药物耐药基因检测对慢乙肝耐药患者治疗的指导意义

The Significance of Detection and Analysis of HBV Nucleoside Drug Resistance Genes in the Treatment of Chronic Hepatitis B Resistant Patients

目的:探讨HBV核苷类药物耐药基因检测对慢乙肝耐药患者治疗的指导意义。方法:将103例未经核苷类似物治疗的慢性乙肝患者随机分为对照组(51例,治疗前不进行耐药检测,患者自愿选择药物)与观察组(52例,治疗前进行预存耐药基因检测),比较两组患者临床血清学指标。结果:治疗48周后,观察组患者的HBeAg阴转率、HBeAg转换率、HBV-DNA转阴率、耐药率、HBV-DNA定量低于对照组(P<0.05)。结论:慢性乙肝耐药患者在治疗前进行HBV核苷类药物耐药基因检测可提高临床治疗效果,减少原发耐药发生,提高抗病毒治疗应答,对慢性乙肝有预防作用。

Objective:To investigate the significance of detection and analysis of HBV nucleoside drug resistance genes in the treatment of chronic hepatitis B resistant patients. Methods:The clinical data of103 patients with chronic hepatitis B who were not treated with nucleoside analogues in our hospital from January 2014 to August 2018 were retrospectively analyzed. They were randomly divided into control group (51 cases without drug resistance testing before treatment, according to patients' voluntary choice of drug treatment) and observation group (52 cases with pre-existing drug resistance gene detection before treatment). The clinical serological indexes of the two groups were compared. Results: After 48 weeks of treatment, the HBeAg negative conversion rate, HBeAg conversion rate, HBV-DNA negative conversion rate, drug resistance rate and HBV-DNA quantitative in the observation group were significantly lower than those in the control group ( P <0.05). Conclusion:Detection of HBV nucleoside drug resistance gene in patients with chronic hepatitis B resistance before treatment can improve the clinical therapeutic effect, reduce the occurrence of primary drug resistance, improve the response to antiviral treatment, and have preventive effect on chronic hepatitis B.